Drug Type Small molecule drug |
Synonyms BMN-195, SMT-1100, SMTC-1100 + [2] |
Target |
Mechanism UTRN activators(Utrophin activators) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC19H15NO3S |
InChIKeyKSGCNXAZROJSNW-UHFFFAOYSA-N |
CAS Registry945531-77-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Muscular Dystrophies | Phase 2 | GB | 04 Oct 2016 | |
Muscular Dystrophy, Duchenne | Phase 2 | US | 01 Jun 2016 | |
Muscular Dystrophy, Duchenne | Phase 2 | GB | 01 Jun 2016 |
Phase 2 | 43 | (Cohort 1: SMT C1100 Formulation 1) | eenjqrelhm(uxgnbomytz) = myucxllboi tqrwtrhcbi (iyapnwojbu, kxwqtiugzu - vtmtjhyqfi) View more | - | 02 Jan 2020 | ||
(Cohort 2: SMT C1100 Formulation 2) | eenjqrelhm(uxgnbomytz) = jxlkmjzkhn tqrwtrhcbi (iyapnwojbu, rawoihvxim - axxkppvyjs) View more |